Merck & Co. (MRK) Shares Bought by Dixon Hubard Feinour & Brown Inc. VA

Dixon Hubard Feinour & Brown Inc. VA increased its holdings in shares of Merck & Co. (NYSE:MRK) by 7.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 24,287 shares of the company’s stock after purchasing an additional 1,705 shares during the period. Dixon Hubard Feinour & Brown Inc. VA’s holdings in Merck & Co. were worth $1,367,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of MRK. Cambridge Investment Research Advisors Inc. raised its holdings in Merck & Co. by 4.3% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 231,223 shares of the company’s stock valued at $14,805,000 after acquiring an additional 9,482 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its holdings in shares of Merck & Co. by 17.4% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 99,267 shares of the company’s stock worth $6,356,000 after buying an additional 14,710 shares in the last quarter. Davidson & Garrard Inc. raised its holdings in shares of Merck & Co. by 5.6% in the 3rd quarter. Davidson & Garrard Inc. now owns 89,763 shares of the company’s stock worth $5,748,000 after buying an additional 4,774 shares in the last quarter. Putnam FL Investment Management Co. acquired a new position in shares of Merck & Co. in the 3rd quarter worth approximately $2,216,000. Finally, Commerce Bank raised its holdings in shares of Merck & Co. by 6.4% in the 3rd quarter. Commerce Bank now owns 1,486,454 shares of the company’s stock worth $95,178,000 after buying an additional 89,923 shares in the last quarter. 74.87% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have recently issued reports on MRK. Jefferies Group set a $55.00 target price on Merck & Co. and gave the stock a “hold” rating in a report on Friday, March 23rd. ValuEngine cut Merck & Co. from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. DZ Bank raised Merck & Co. from a “hold” rating to a “buy” rating in a report on Tuesday, February 13th. Morgan Stanley increased their target price on Merck & Co. from $60.00 to $63.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 7th. Finally, Credit Suisse Group dropped their target price on Merck & Co. from $67.00 to $66.00 and set an “outperform” rating for the company in a report on Monday, February 5th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Merck & Co. presently has an average rating of “Buy” and an average price target of $65.87.

Merck & Co. opened at $59.07 on Friday, according to MarketBeat. The company has a market cap of $159.61 billion, a P/E ratio of 14.84, a price-to-earnings-growth ratio of 2.25 and a beta of 0.76. Merck & Co. has a one year low of $59.04 and a one year high of $59.65. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.10 and a current ratio of 1.42.

Merck & Co. (NYSE:MRK) last released its quarterly earnings results on Tuesday, May 1st. The company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $1.00 by $0.05. The business had revenue of $10.04 billion for the quarter, compared to analyst estimates of $10.09 billion. Merck & Co. had a return on equity of 30.93% and a net margin of 4.31%. Merck & Co.’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.88 EPS. analysts forecast that Merck & Co. will post 4.23 earnings per share for the current fiscal year.

In other Merck & Co. news, insider Weir Mirian M. Graddick sold 24,000 shares of the stock in a transaction on Monday, April 16th. The stock was sold at an average price of $58.00, for a total value of $1,392,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Julie L. Gerberding sold 9,972 shares of the stock in a transaction on Tuesday, May 15th. The shares were sold at an average price of $59.66, for a total value of $594,929.52. The disclosure for this sale can be found here. 0.32% of the stock is currently owned by company insiders.

Merck & Co. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply